In conclusion, CCL18—but not OX40L—may be a useful diagnostic biomarker in the assessment of patients with IIMs-ILD, and it seems to be particularly promising in the early identification of the PF-ILD forms. This evidence concerns the gene CCL18 and interstitial lung disease.